Try free for 30 days
-
The Great American Drug Deal
- A New Prescription for Innovative and Affordable Medicines
- Narrated by: Sean Pratt
- Length: 8 hrs and 27 mins
Failed to add items
Add to basket failed.
Add to Wish List failed.
Remove from Wish List failed.
Follow podcast failed
Unfollow podcast failed
Buy Now for $26.99
No valid payment method on file.
We are sorry. We are not allowed to sell this product with the selected payment method
Listeners also picked
-
The Billion Dollar Molecule
- One Company's Quest for the Perfect Drug
- By: Barry Werth
- Narrated by: Stephen Bowlby
- Length: 18 hrs and 25 mins
- Unabridged
-
Overall
-
Performance
-
Story
Join journalist Barry Werth as he pulls back the curtain on Vertex, a start-up pharmaceutical company, and witness firsthand the intense drama being played out in the pioneering and hugely profitable field of drug research. Founded by Joshua Boger, a dynamic Harvard- and Merck-trained scientific whiz kid, Vertex is dedicated to designing - atom by atom - both a new life-saving immunosuppressant drug and a drug to combat the virus that causes AIDS.
-
A Concise Guide to Macroeconomics, Second Edition
- What Managers, Executives, and Students Need to Know
- By: David A. Moss
- Narrated by: Christopher Kipiniak
- Length: 4 hrs and 50 mins
- Unabridged
-
Overall
-
Performance
-
Story
This guidebook covers the essentials of macroeconomics and examines, in a simple and intuitive way, the core ideas of output, money, and expectations. Early chapters leave you with an understanding of everything from fiscal policy and central banking to business cycles and international trade. Later chapters provide a brief monetary history of the United States as well as the basics of macroeconomic accounting. You'll learn why countries trade, why exchange rates move, and what makes an economy grow.
-
Genentech
- The Beginnings of Biotech
- By: Sally Smith Hughes
- Narrated by: Suzie Althens
- Length: 7 hrs and 12 mins
- Unabridged
-
Overall
-
Performance
-
Story
In the fall of 1980, Genentech, Inc., a little-known California genetic engineering company, became the overnight darling of Wall Street, raising over $38 million in its initial public stock offering. Lacking marketed products or substantial profit, the firm nonetheless saw its share price escalate from $35 to $89 in the first few minutes of trading. Coming at a time of economic recession and declining technological competitiveness in the United States, the event ignited a period of speculative frenzy over biotechnology.
-
-
Great piece of history
- By Ryan G. on 27-02-2023
-
The AI Revolution in Medicine
- GPT-4 and Beyond
- By: Peter Lee, Carey Goldberg, Isaac Kohane
- Narrated by: J. Hunter Ackerman
- Length: 7 hrs and 24 mins
- Unabridged
-
Overall
-
Performance
-
Story
Just months ago, millions of people were stunned by ChatGPT's amazing abilities–and its bizarre hallucinations. But that was 2022. GPT-4 is now here, with smarter, more accurate, and deeper technical knowledge. GPT-4 and its competitors and followers are on the verge of transforming medicine. But with lives on the line, you need to understand these technologies–stat.
-
Reality-Based Leadership
- Ditch the Drama, Restore Sanity to the Workplace, and Turn Excuses into Results
- By: Cy Wakeman
- Narrated by: Deanna Hurst
- Length: 5 hrs and 40 mins
- Unabridged
-
Overall
-
Performance
-
Story
In Reality-Based Leadership, expert Fast Company blogger Cy Wakeman reveals how to be the kind of leader who changes the way people think about and perceive their circumstances - one who deals with the facts, clarifies roles, gives clear and direct feedback, and insists that everyone do the same - without drama or defensiveness. Filled with dynamic examples and innovative tools, this book shows you how to become a reality-based leader.
-
-
Just what I needed.
- By Anonymous User on 29-08-2022
-
From Breakthrough to Blockbuster
- The Business of Biotechnology
- By: Donald L. Drakeman, Lisa N. Drakeman, Nektarios Oraiopoulos
- Narrated by: Chris Andrew Ciulla
- Length: 7 hrs and 1 min
- Unabridged
-
Overall
-
Performance
-
Story
Beginning in the 1970s, several scientific breakthroughs promised to transform the creation of new medicines. As investors sought to capitalize on these Nobel Prize-winning discoveries, the biotech industry grew to thousands of small companies around the world. Each sought to emulate what the major pharmaceutical companies had been doing for a century or more, but without the advantages of scale, scope, experience, and massive resources. From Breakthrough to Blockbuster focuses on both the companies themselves and the broader biotech ecosystem that supports them.
-
The Billion Dollar Molecule
- One Company's Quest for the Perfect Drug
- By: Barry Werth
- Narrated by: Stephen Bowlby
- Length: 18 hrs and 25 mins
- Unabridged
-
Overall
-
Performance
-
Story
Join journalist Barry Werth as he pulls back the curtain on Vertex, a start-up pharmaceutical company, and witness firsthand the intense drama being played out in the pioneering and hugely profitable field of drug research. Founded by Joshua Boger, a dynamic Harvard- and Merck-trained scientific whiz kid, Vertex is dedicated to designing - atom by atom - both a new life-saving immunosuppressant drug and a drug to combat the virus that causes AIDS.
-
A Concise Guide to Macroeconomics, Second Edition
- What Managers, Executives, and Students Need to Know
- By: David A. Moss
- Narrated by: Christopher Kipiniak
- Length: 4 hrs and 50 mins
- Unabridged
-
Overall
-
Performance
-
Story
This guidebook covers the essentials of macroeconomics and examines, in a simple and intuitive way, the core ideas of output, money, and expectations. Early chapters leave you with an understanding of everything from fiscal policy and central banking to business cycles and international trade. Later chapters provide a brief monetary history of the United States as well as the basics of macroeconomic accounting. You'll learn why countries trade, why exchange rates move, and what makes an economy grow.
-
Genentech
- The Beginnings of Biotech
- By: Sally Smith Hughes
- Narrated by: Suzie Althens
- Length: 7 hrs and 12 mins
- Unabridged
-
Overall
-
Performance
-
Story
In the fall of 1980, Genentech, Inc., a little-known California genetic engineering company, became the overnight darling of Wall Street, raising over $38 million in its initial public stock offering. Lacking marketed products or substantial profit, the firm nonetheless saw its share price escalate from $35 to $89 in the first few minutes of trading. Coming at a time of economic recession and declining technological competitiveness in the United States, the event ignited a period of speculative frenzy over biotechnology.
-
-
Great piece of history
- By Ryan G. on 27-02-2023
-
The AI Revolution in Medicine
- GPT-4 and Beyond
- By: Peter Lee, Carey Goldberg, Isaac Kohane
- Narrated by: J. Hunter Ackerman
- Length: 7 hrs and 24 mins
- Unabridged
-
Overall
-
Performance
-
Story
Just months ago, millions of people were stunned by ChatGPT's amazing abilities–and its bizarre hallucinations. But that was 2022. GPT-4 is now here, with smarter, more accurate, and deeper technical knowledge. GPT-4 and its competitors and followers are on the verge of transforming medicine. But with lives on the line, you need to understand these technologies–stat.
-
Reality-Based Leadership
- Ditch the Drama, Restore Sanity to the Workplace, and Turn Excuses into Results
- By: Cy Wakeman
- Narrated by: Deanna Hurst
- Length: 5 hrs and 40 mins
- Unabridged
-
Overall
-
Performance
-
Story
In Reality-Based Leadership, expert Fast Company blogger Cy Wakeman reveals how to be the kind of leader who changes the way people think about and perceive their circumstances - one who deals with the facts, clarifies roles, gives clear and direct feedback, and insists that everyone do the same - without drama or defensiveness. Filled with dynamic examples and innovative tools, this book shows you how to become a reality-based leader.
-
-
Just what I needed.
- By Anonymous User on 29-08-2022
-
From Breakthrough to Blockbuster
- The Business of Biotechnology
- By: Donald L. Drakeman, Lisa N. Drakeman, Nektarios Oraiopoulos
- Narrated by: Chris Andrew Ciulla
- Length: 7 hrs and 1 min
- Unabridged
-
Overall
-
Performance
-
Story
Beginning in the 1970s, several scientific breakthroughs promised to transform the creation of new medicines. As investors sought to capitalize on these Nobel Prize-winning discoveries, the biotech industry grew to thousands of small companies around the world. Each sought to emulate what the major pharmaceutical companies had been doing for a century or more, but without the advantages of scale, scope, experience, and massive resources. From Breakthrough to Blockbuster focuses on both the companies themselves and the broader biotech ecosystem that supports them.
-
The Great Mental Models
- General Thinking Concepts
- By: Shane Parrish
- Narrated by: Shane Parrish
- Length: 3 hrs and 23 mins
- Unabridged
-
Overall
-
Performance
-
Story
The Great Mental Models: General Thinking Concepts is the first book in The Great Mental Models series designed to upgrade your thinking with the best, most useful and powerful tools so you always have the right one on hand. This volume details nine of the most versatile all-purpose mental models you can use right away to improve your decision making, your productivity, and how clearly you see the world.
-
-
Dreadful Narration - Returning the book.
- By Russell on 03-05-2019
-
Future Care
- Sensors, Artificial Intelligence, and the Reinvention of Medicine
- By: Dr. Jag Singh
- Narrated by: Mike Chamberlain
- Length: 11 hrs and 41 mins
- Unabridged
-
Overall
-
Performance
-
Story
A renowned cardiologist and Harvard professor spells out the future digital shift of medicine—and how it will impact the lives not only of patients and health care professionals but of all humans.
-
Venture Deals, 4th Edition
- Be Smarter than Your Lawyer and Venture Capitalist
- By: Brad Feld, Jason Mendelson
- Narrated by: Barry Abrams
- Length: 11 hrs and 4 mins
- Unabridged
-
Overall
-
Performance
-
Story
The founders and driving force behind the Foundry Group - a venture capital firm focused on investing in early-stage information technology companies - Brad and Jason have been involved in hundreds of venture capital financings. Their investments range from small startups to large Series A venture financing rounds. The new edition of Venture Deals continues to show fledgling entrepreneurs the inner-workings of the VC process, from the venture capital term sheet and effective negotiating strategies to the initial seed and the later stages of development.
-
The Business of Venture Capital (3rd Edition)
- The Art of Raising a Fund, Structuring Investments, Portfolio Management, and Exits,
- By: Mahendra Ramsinghani
- Narrated by: Mike Lenz
- Length: 13 hrs and 58 mins
- Unabridged
-
Overall
-
Performance
-
Story
Since its initial publication, The Business of Venture Capital has been hailed as the definitive, most comprehensive book on the subject. Now in its third edition, this market-leading guide explains the multiple facets of the business of venture capital, from raising venture funds, to structuring investments, to generating consistent returns, to evaluating exit strategies.
-
-
I have found this the best single guide on venture
- By Amazon Customer on 24-11-2022
-
Drugs, Money, and Secret Handshakes
- The Unstoppable Growth of Prescription Drug Prices
- By: Robin Feldman
- Narrated by: Randye Kaye
- Length: 4 hrs and 49 mins
- Unabridged
-
Overall
-
Performance
-
Story
In the warped world of prescription drug pricing, generic drugs can cost more than branded ones, old drugs can be relaunched at astronomical prices, and low-cost options are shut out of the market. In Drugs, Money and Secret Handshakes, Robin Feldman shines a light into the dark corners of the pharmaceutical industry to expose a web of shadowy deals in which higher-priced drugs receive favorable treatment and patients are channeled toward the most expensive medicines.
-
Drugs and the FDA
- Safety, Efficacy, and the Public's Trust
- By: Mikkael A. Sekeres
- Narrated by: Mike Lenz
- Length: 8 hrs and 40 mins
- Unabridged
-
Overall
-
Performance
-
Story
Food and Drug Administration approval for COVID-19 vaccines and the controversial Alzheimer's drug Aduhelm made headlines, but few of us know much about how the agency does its work. Why is the FDA the ultimate United States authority on a drug's safety and efficacy? In Drugs and the FDA, Mikkael Sekeres—a leading oncologist and former chair of the FDA's cancer drug advisory committee—tells the story of how the FDA became the most trusted regulatory agency in the world.
Publisher's Summary
Developing life-changing drugs is risky and expensive, but that’s not what makes them unaffordable.
Drug pricing is a staple of every news cycle and political debate. And while we’ve struggled for decades to agree on solutions that serve all patients without jeopardizing the invention of new medicines, many Americans suffer because they can’t afford the drugs they need. Do we really have to choose between affordability and innovation?
In The Great American Drug Deal, scientist and industry expert Peter Kolchinsky answers this question with a decisive "no". The pharmaceutical industry’s commitment to creating new lifesaving drugs destined to become inexpensive generics can be balanced by the healthcare system’s commitment to making those drugs affordable for all patients - a biotech social contract.
Through deep research and compelling stories of breakthroughs and breakdowns, Kolchinsky presents solutions for striking a balance that are bold yet realistic and tackle today’s most pressing questions, including:
- Why doesn’t insurance make drugs affordable?
- How can we prevent price-jacking of older drugs?
- Why are drugs more expensive in America than elsewhere?
- How can we guarantee that all medicines eventually go generic so they are only temporarily expensive?
- What systemic failures led to the opioid crisis, and how can we prevent the next one?
The Great American Drug Deal offers clear-eyed scrutiny of all players in the industry and examines vital ideas for closing loopholes, encouraging investment, dealing with bad actors, and educating consumers. It’s time we resolve to support patients and fuel discoveries that ease suffering now and for generations to come.